Journal for ImmunoTherapy of Cancer Impact Factor 2026: 10.1, Quartile

Publishing your own paper?

Get it ready for the right journal with a PhD expert in your field.

Manuscript Auditing

A PhD reviewer in your exact area sends a structured, section-by-section critical review.

AI plagiarism and similarity report included
Secure, confidential upload

Audit duration: within 1 weekCheck price →

If the journal needs LaTeX

LaTeX Template Conversion

We convert your manuscript into the LaTeX template your target journal requires.

Check price →

If your paper was out of scope

Journal Selection & Submission

Up to 5 journals matched to your indexing (SCIE / Scopus) and quartile
Submission handled, with weekly updates

With LaTeX conversion: within 2 Working DaysCheck price →

What is ScholarsColab?

ScholarsColab is a freelancing platform built for researchers, with a pool of research doctorates registered to mentor them. Hire one in your research area and cut your research timeline from 2 years to 2 months.

Know more →

At a glanceJournal for ImmunoTherapy of Cancer is listed in SCIE, Scopus, JCR 2024. Published by BMJ, it has 5,903 published works, cited 214,512 times (h-index 184). Its impact factor* of 10.1 ranks it 20 of 347 in Oncology. It is a fully open access journal listed in DOAJ, with an article fee of about US$2,490. 88% of its recent research articles name a funder, most often National Natural Science Foundation of China. It has 1 retraction on record. Papers by ScholarsColab mentors and the researchers we track appear here as soon as they publish in it. Data updated 22 October 2026.

Official website Check my manuscript first

Impact factor*10.1Rank 20 of 347 in Oncology IndexingSCIEScopusJCR 2024Confirm on the official lists before you submit Article fee (APC)US$2,490See if your author team can get a waiver Retractions1On record, with the reasons and years

01Impact factor

Impact factor of Journal for ImmunoTherapy of Cancer (2026)

Impact factor (2-year)10.1calculated by ScholarsColab

Rank in category#20of 347 by citedness

APC (listed)US$2,490open access

h-index184

Papers published5,903cited 214,512 times

The impact factor shown here is the 2-year mean citedness: citations received in a year by the papers Journal for ImmunoTherapy of Cancer published in the two previous years, divided by the number of those papers. That is the same formula as the Journal Impact Factor, calculated by ScholarsColab. The journal is listed in JCR 2024, so it also has an official Journal Impact Factor published by Clarivate, which can differ because it counts citations from Web of Science journals only.

Rank in its subject categories

Oncologyrank 20 of 347 journals
Immunologyrank 11 of 189 journals

Ranks here compare journals of the same Web of Science category in our data by 2-year citedness; they are not the official JCR rank.

Quartile of Journal for ImmunoTherapy of Cancer

A journal's quartile (Q1 to Q4) is its position within a subject category: Q1 is the top quarter. The official quartiles are published by Clarivate in Journal Citation Reports (by Journal Impact Factor, in Web of Science categories) and by Scimago as the SJR quartile (in Scopus categories). Journal for ImmunoTherapy of Cancer is listed in JCR 2024, so its JCR quartile is in Journal Citation Reports. It is indexed in Scopus, so Scimago shows its SJR quartile. ScholarsColab does not show a quartile until it can show the official one; the impact factor and rank above are calculated from open data.

Citations and papers per year

Citations per year

Papers per year

Open access (listed in DOAJ); article processing charge listed at about US$2,490.

Please check the final impact factor. The impact factor and APC on this page are calculated by ScholarsColab (updated 17 October 2026) and can differ from the official values. Confirm the current impact factor and charges on the journal’s website or in Clarivate’s Journal Citation Reports before you submit.

Is your paper a fit for Journal for ImmunoTherapy of Cancer?

Most desk rejections come from a scope mismatch. Compare your title and abstract with what this journal really publishes. Free, no sign-up, about 2 minutes.

Check my paper for this journal Or find journals that fit my paper

Need a faster review? The fastest journals in Oncology accept papers in a median of 3 days.

All fastest journals in this field

APC waivers and discounts for Journal for ImmunoTherapy of Cancer APC about US$2,490

BMJ: full waiver only when every author is in a country on BMJ's list and the research is unfunded; partial discounts case by case. Authors in 91 countries get a full waiver.

Check the APC for my country

02Retractions

Retractions and research integrity at Journal for ImmunoTherapy of Cancer

Retractions, last 10 years11 in all years

Per 1,000 papers0.3of 3,799 papers in 10 years

Most common reasons (a retraction can have several):

Legal Reasons and/or Threats1

Journal for ImmunoTherapy of Cancer has 1 retracted paper on record, the latest in May 2020. A retraction count is not a verdict on a journal: large journals publish more and journals that investigate actively retract more. The trend and the reasons tell you more than the number.

Choosing between journals? Read how to check a journal, or let a PhD expert shortlist reliable journals for your manuscript.

Updated 27 October 2026. Journals are matched by name, so a renamed journal may be missing or combined. ScholarsColab is not affiliated with this journal.

03Funders

Who funds research published in Journal for ImmunoTherapy of Cancer

Articles naming a funder88%of 200 recent articles

Funders named most often

National Natural Science Foundation of China55

National Cancer Institute12

Deutsche Forschungsgemeinschaft8

National Institutes of Health8

Basic and Applied Basic Research Foundation of Guangdong Province6

A high share of funded papers usually means the journal is a common choice for grant-supported work in its field. If your funder pays article processing charges, or your country qualifies for a waiver, check what applies to your author team with the free APC waiver checker.

Based on up to 200 research articles this journal published in the last 24 months. Not every article lists its funders, so the share can be lower than the real one. Updated: 29 October 2026.

04Indexing

Indexing of Journal for ImmunoTherapy of Cancer

List	Status
Science Citation Index Expanded (SCIE)	✓ Listed
Social Sciences Citation Index (SSCI)	Not listed
Arts & Humanities Citation Index (AHCI)	Not listed
Emerging Sources Citation Index (ESCI)	Not listed
Scopus	✓ Listed
Journal Citation Reports 2024	✓ Listed

ISSN: 2051-1426
Publisher: Bmj all its journals →
Subjects: Oncology, Immunology

From the indexing lists used on ScholarsColab, updated 1 March 2026. Indexing can change: confirm on the Web of Science Master Journal List or the Scopus source list before submitting. Official Journal Impact Factors and JCR quartiles are published by Clarivate; the impact factor on this page is calculated by ScholarsColab (see how the impact factor works).

Verify the indexing yourself

Each link opens the official record for this journal, searched by its ISSN where we have one.

05How to submit

How to submit to Journal for ImmunoTherapy of Cancer

Read the guide for authors. It sets the article types, word limit, reference style and file format that Journal for ImmunoTherapy of Cancer accepts. You find it on the official website of the journal, usually under "For authors" or "Submit".
Format to the journal's style. Check whether it wants a Word file, a LaTeX file or a PDF for the first submission, and follow its reference style; many journals accept any clear format at first and ask for their style only after acceptance.
Check the fit. Read the aims and scope and a few recent issues; papers outside the scope are the most common reason for a desk rejection. The Journal Finder shows journals that published the closest work.
Plan the fee. Journal for ImmunoTherapy of Cancer is fully open access, with an article fee of about US$2,490 after acceptance. See whether your author team qualifies for a waiver with the free APC waiver checker.
Check your manuscript before you submit. The free Submission Readiness Check asks the seven questions our reviewers ask in every audit and takes about 2 minutes.

06Reviewer comments

Reviewer comments and rejection reasons for Journal for ImmunoTherapy of Cancer

No reviewer or editor comments have been shared for this journal yet. Did you submit here? Help other researchers by sharing the comments you received, anonymously.

Across the reviewer comments researchers have shared with us, the points raised most often are figures, tables and equations (21%), literature and references (12%) and novelty and contribution (10%). Before you submit to Journal for ImmunoTherapy of Cancer, a Manuscript Audit by a PhD reviewer in your area checks your paper against exactly these points.

Audit my paper before I submit →

Worried about the English? Manuscript editing by editors in your subject: see the price →

Not sure yet? Check if your paper is ready for this journal: free, no AI, under 5 seconds

07Same subject

Oncology journals with a similar impact factor*

The journals next to Journal for ImmunoTherapy of Cancer when the 328 journals of Oncology in our data are ranked by impact factor*:

Rank	Journal	Impact factor*	Indexing	Open access
16	Seminars in Cancer Biology	11.2	SCIE	Subscription
17	Trends in cancer	11.1	SCIE	Subscription
18	Cancer Letters	10.6	SCIE	Subscription
19	Cancer Treatment Reviews	10.4	SCIE	Subscription
21	npj Precision Oncology	9.01	SCIE	Fully open access
22	JAMA Oncology	8.62	SCIE	Subscription
23	BioDrugs	8.38	SCIE	Subscription
24	Blood Cancer Journal	7.89	SCIE	Fully open access

*Impact factor calculated by ScholarsColab (2-year citedness), not the official Clarivate value.

FreeNo AI

Is Journal for ImmunoTherapy of Cancer right for your paper? Find the right journal

Paste your title, keywords or abstract. See the journals that published the closest papers, with indexing, impact factor, review time and APC.

Try:

Publishing open access? Your author team may not have to pay the APC. Free APC waiver check for your country→

How it works

No AI or language model is used. Your words are matched against the titles of 157,109 real published journal papers, by our mentors and by other researchers (shown without names); journals are ranked by how many closely matching papers they published. Indexing comes from the SCIE, SSCI, AHCI, ESCI, Scopus and JCR 2024 lists, matched by journal name; the impact factor is calculated by ScholarsColab, not the official Clarivate value, and no quartile is shown until the official JCR or SJR quartile can be; review time is the median days from submission to acceptance (not every publisher publishes these dates). Always check a journal’s scope and current indexing before submitting.

Want a PhD expert to shortlist and handle the submission? Journal Selection & Submission matches your manuscript to up to 5 suitable journals by indexing and quartile. Check price →

08Questions

Frequently asked questions

What is the impact factor of Journal for ImmunoTherapy of Cancer?

Based on ScholarsColab citation data (October 2026), the 2-year impact factor of Journal for ImmunoTherapy of Cancer is 10.1: papers it published in the two previous years were cited 10.1 times on average in a year. The journal is listed in JCR 2024, so Clarivate also publishes an official Journal Impact Factor, which can differ.

What is the h-index of Journal for ImmunoTherapy of Cancer?

The h-index of Journal for ImmunoTherapy of Cancer is 184 (October 2026): 184 of its papers have each been cited at least 184 times. Its i10-index is 3,280.

What is the APC of Journal for ImmunoTherapy of Cancer?

The listed article processing charge (APC) is about US$2,490 for Journal for ImmunoTherapy of Cancer, an open access journal (data from October 2026). APCs change and can differ by article type, country or discounts, so confirm the current charge on the journal’s website before submitting.

What is the quartile of Journal for ImmunoTherapy of Cancer?

Is Journal for ImmunoTherapy of Cancer indexed in Scopus?

Yes. Journal for ImmunoTherapy of Cancer appears in the Scopus list, according to the indexing lists used on ScholarsColab (updated 1 March 2026). Always confirm the current status on the official list before submitting.

Is Journal for ImmunoTherapy of Cancer an SCIE journal?

Yes. Journal for ImmunoTherapy of Cancer is listed in the Science Citation Index Expanded (SCIE), according to the indexing lists used on ScholarsColab (updated 1 March 2026). Always confirm the current status on the official list before submitting.

Is Journal for ImmunoTherapy of Cancer in Journal Citation Reports (JCR)?

Yes. Journal for ImmunoTherapy of Cancer is listed in JCR 2024, so it has a Journal Impact Factor. For the current impact factor and quartile, check Journal Citation Reports.

Does Journal for ImmunoTherapy of Cancer offer an APC waiver?

Journal for ImmunoTherapy of Cancer follows the policy of BMJ: full waiver only when every author is in a country on BMJ's list and the research is unfunded; partial discounts case by case. Rules verified 27 October 2026; confirm on the publisher's page.

Has Journal for ImmunoTherapy of Cancer retracted papers?

Yes. 1 retracted paper are on record for Journal for ImmunoTherapy of Cancer, 1 of them in the last 10 years; the most common reasons are legal reasons and/or threats. A retraction count alone is not a verdict on a journal; look at the trend and the reasons. Data updated October 2026.

Who funds research published in Journal for ImmunoTherapy of Cancer?

88% of 200 recent research articles in Journal for ImmunoTherapy of Cancer name a funder; the funders named most often are National Natural Science Foundation of China, National Cancer Institute, Deutsche Forschungsgemeinschaft.